Cardiff Oncology’s Phase III Push Puts Trial Durability in the Spotlight
Cardiff Oncology’s UBS conference update puts its Phase III timeline—and the durability question—at the center of the CRDF biotech story.
Roche’s FDA Approval Adds Momentum to Its Advanced Breast Cancer Franchise
Roche’s FDA approval for an advanced breast cancer pill gives North American healthcare investors a fresh regulatory catalyst to assess.
AstraZeneca’s Two FDA Approvals Expand Its U.S. Growth Pipeline
AstraZeneca’s two U.S. FDA approvals broaden its commercial portfolio and give investors a fresh signal on pipeline execution.
Acadia’s Mixed Alzheimer’s Psychosis Readout Keeps ACAD Investors Focused on Phase 3
Acadia’s RADIANT study missed its primary endpoint but hit a key secondary endpoint, leaving ACAD with near-term uncertainty and a Phase 3 c…
Aytu BioPharma Buyout Sets $2.70 Per-Share Target for Deal Arbitrage Traders
Rosemont’s proposed acquisition of Aytu BioPharma establishes a fixed $2.70-per-share reference point for AYTU deal analysis.
Eli Lilly’s $1.5 Billion Calytrix Deal Signals a Push Beyond Obesity Drugs
Eli Lilly’s up-to-$1.5 billion Calytrix Bio acquisition points to broader pipeline ambitions as biotech consolidation continues.
MiniMed Stock Gains as FDA Clearance Puts Tubeless Pump in the Spotlight
MiniMed stock gained after FDA clearance of its tubeless insulin pump, giving the $5.29 billion company a potential near-term catalyst.
Summit Therapeutics Plunges After FDA Rejects Ivonescimab Lung Cancer Application
Summit Therapeutics shares fell 19% to 20% in premarket trading after the FDA rejected ivonescimab over insufficient overall survival benefi…
Novo Nordisk’s Wegovy Pediatric Trial Points to Potential New Obesity Market
Novo Nordisk’s pediatric Wegovy trial could broaden its obesity franchise, while raising the stakes in competition with Eli Lilly.
CG Oncology Stock Rises on Positive Phase 3 Bladder Cancer Results
CG Oncology shares moved higher after positive topline Phase 3 data for cretostimogene, with full PIVOT-006 results due December 2.
Summit Therapeutics Stock Plunges After FDA Rejects Lung Cancer Drug Application
Summit Therapeutics shares fell more than 19% in premarket trading after the FDA issued a Complete Response Letter for its lung cancer drug.
MiNK Therapeutics’ Phase 2 Lung-Injury Trial Sets Up FDA Design Catalyst
MiNK Therapeutics’ randomized Phase 2 trial of agenT-797 could gain strategic clarity through a planned FDA discussion before year-end.











